IHC analysis of tumor samples collected from the 051009 PDX model at the end of therapy showed that P-FAK expression levels were significantly higher in the crizotinib monotherapy compared to the combination therapy, which was consistent with the results obtained in the NUGC-4 tumors (Figure 3 J, K). Here, PTK2 is linked to neoplasm.